CATALYSTYahoo • 1d ago
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.
Why ARGX Stock advanced +0.68% Today — RQD Quant Desk Flash
$897.85 +0.68% NASDAQ • Public Delayed / 60s Snapshot
argenx SE (ARGX) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C • HOLD / WATCH
Cap $55.72B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
WHALE OPTIONS TUG-OF-WAR:53% Call Buyers ($5.3M)
47% PutsMax Pain: $880.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ARGX Stock advanced +0.68% Today — RQD Quant Desk Flash
argenx SE (ARGX) advanced +0.68% to $897.85 as options desks priced 53% call premium vs. 47% put protection around the $880 max-pain magnet. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 57% of its 52-week range ($661.85 – $1072.75) with RSI-14 at 50.4 (NEUTRAL RANGE).
- ▸Whale Options Positioning: $5.3M in bullish call flow vs. $4.7M in put flow (Put/Call 0.88x, implied earnings swing ±7%).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 41% gross margin and $1.2B annual free cash flow.
Live ARGX Headlines & Catalysts
MARKET WIREYahoo • 2d ago
European Equities Traded in the US as American Depositary Receipts Rise in Thursday TradingEuropean equities traded in the US as American depositary receipts were tracking higher late Thursda
MARKET WIREBenzinga • 4d ago
Citigroup Maintains Buy on argenx, Lowers Price Target to $1232Citigroup analyst Samantha Semenkow maintains argenx (NASDAQ:ARGX) with a Buy and lowers the price target from $1301 to $1232.
MARKET WIREBenzinga • 5d ago
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Todayargenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 12.9% on an annualized basis producing an average annual return of 23.66%. Currently, argenx has a market capitalization of $55.07 billion.
CATALYSTYahoo • 7d ago
argenx (ENXTBR:ARGX) Stock Looks Overvalued After Its 202% Five Year Runargenx has delivered powerful long term gains, and the latest jump on fresh clinical data has put an even brighter spotlight on whether the current share price is adequately supported by its earnings. With the stock now
CATALYSTYahoo • 7d ago
argenx (ENXTBR:ARGX) Posted Q3 2026 Results, Is It Fully Priced?argenx (ENXTBR:ARGX) just released its Q3 2026 results, giving investors a detailed look at how its autoimmune portfolio is translating into revenue, profit and earnings per share. argenx shares trade at €782.2, with a 7
MARKET WIREYahoo • 7d ago
argenx (ENXTBR:ARGX) Reports Positive Phase 3 Data In Autoimmune MyositisArgenx (ENXTBR:ARGX) reported positive topline Phase 3 ALKIVIA trial results for VYVGART in autoimmune myositis patients. The study met its primary endpoint, showing clinically meaningful improvement over placebo in both
CATALYSTYahoo • 7d ago
Argenx (ENXTBR:ARGX) Stock Faces Margin Questions After Q3 EarningsArgenx came into this Q3 2026 report with a rich biotech valuation and a reputation as a high conviction growth story. Yet the stock closed at €782.2 on 23 October, roughly flat over the past week and soft over the past
CATALYSTYahoo • 8d ago
Argenx's Vyvgart Sales Growth, Pipeline Progress Support Outlook, Oppenheimer SaysArgenx's (ARGX) Q3 results highlighted continued growth in Vyvgart sales, while its acquisition of F
CATALYSTYahoo • 8d ago
Argenx's Vyvgart Beats Expectations With Focus Shifting to December Data, RBC SaysArgenx's (ARGX) Vyvgart sales beat expectations in Q3, with investors focused on upcoming multifocal
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live ARGX Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
ARGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +14.22%📐 HORIZONTAL RANGE
2026-10-30O $896.8H $916.1L $890.0C $892.9VOL 462.4K
RES: $1,186.5SUP: $776.9SMA50: $943.6SMA200: $854.7
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ARGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth
vs. +18.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ARGX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ARGX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ARGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
ARGX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ARGX stock moving today?
Why ARGX Stock advanced +0.68% Today — RQD Quant Desk Flash. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.